Literature DB >> 34482844

Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism.

Natália Lima Pessoa1,2, Aline Almeida Bentes3,4, Andrea Lucchesi de Carvalho4, Thaís Bárbara de Souza Silva2, Pedro Augusto Alves2, Erik Vinicius de Sousa Reis2, Tayse Andrade Rodrigues1,5, Erna Geessien Kroon1, Marco Antônio Campos6.   

Abstract

BACKGROUND: Covid-19 has the respiratory tract as the main target of infection, and patients present mainly dyspnea, pneumonia, dry cough, and fever. Nevertheless, organs outside the respiratory tract had been reported in recent studies, including the gastrointestinal tract and liver. The host innate immune system recognizes pathogen-associated molecular patterns (PAMPs) through their pattern recognition receptor (PRRs). Toll-like receptor 7 (TLR-7) is a pattern recognition receptor recognizing ssRNA (SARS-CoV-2 is an ssRNA). Polymorphisms are characterized by two or more alternative forms of a distinct phenotype in the same population. Polymorphisms in tlrs genes can negatively influence the immune response to infectious diseases. There are several references in the literature to non-synonymous single nucleotide (rs) polymorphisms related to several genes. Some of them are important for the innate immunity, as rs 179008 (tlr-7), rs3775291 (tlr3), rs8177374 (tir domain-containing adaptor protein, tirap), rs1024611 (monocyte chemoattractant protein-1, mcp-1) and rs61942233 (2'-5'-oligoadenylate synthase-3, oas-3). CASE
PRESENTATION: We identified a 5-year-old-male child with gastrointestinal symptoms and fever presenting acholic stool and jaundice, who was positive for SARS-CoV-2 IgM, IgA, and IgG and presenting the Gln11Leu rs 179008 in tlr-7. The child presented high levels of aspartate aminotransferase, alanine aminotransferase, bilirubin, C-reactive protein, D-dimer, gamma-glutamyl transferase, alkaline phosphatase, and was negative for serological tests for hepatitis A, B, C, E, HIV 1 and 2, herpes virus, cytomegalovirus, Epstein-Barr virus, and negative for RTqPCR for Influenza A and B, RSV and SARS-CoV-2. We also investigated other SNPs in the tlr-3 (rs3775291), tirap (rs8177374), mcp-1 (rs1024611), and oas-3 (rs61942233) genes, and no mutation was detected. After an interview with the child's caregivers, any possible accidental ingestion of drugs or hepatotoxic substances was ruled out.
CONCLUSION: To our knowledge, this is the first report of a SARS-CoV-2 caused hepatitis in a male child that has the tlr-7 Gln11Leu rs 179008, which could impair an efficient initial immune response. The knowledge of the patient's immune deficiency could improve the treatment to correct this deficiency with specific medications.
© 2021. The Author(s).

Entities:  

Keywords:  Children; Covid-19; Hepatitis; Innate immune defense; SARS-CoV-2; Single nucleotide polymorphism; TLR-7; Toll-like receptor 7 Gln11Leu; rs 179008

Mesh:

Substances:

Year:  2021        PMID: 34482844      PMCID: PMC8418785          DOI: 10.1186/s12985-021-01656-3

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Background

Coronavirus disease 2019 (COVID-19) is a significant global public health problem. The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), a single-stranded RNA (ssRNA) virus, has the respiratory tract as the main target of infection, and patients present mainly dyspnea, pneumonia, dry cough, and fever [1]. Nevertheless, the involvement of organs outside the respiratory tract had been reported in recent studies, including the gastrointestinal tract and liver [2-4]. Liver damage of varying degrees was present in 58–78% of patients [3]. The host immune response to SARS-CoV-2 infection plays an important role in the severity of the disease [5]. It is responsible for recognizing pathogen-associated molecular patterns (PAMPs) through their pattern recognition receptor (PRRs). Toll-like receptor 7 (TLR-7) is a PRR that recognizes ssRNA [6]. Polymorphisms are characterized by two or more alternative forms of a distinct phenotype in the same population, and polymorphisms in TLRs can negatively influence the immune response to infectious diseases [7]. There are several references in the literature to non-synonymous single nucleotide (rs) polymorphisms related to several genes (https://www.genecards.org/). Some of them are important for the innate immunity, as rs179008 (tlr-7), rs3775291 (tlr3), rs8177374 (tir domain-containing adaptor protein, tirap), rs1024611 (monocyte chemoattractant protein-1, mcp-1) and rs61942233 (2′-5′-oligoadenylate synthase-3, oas-3) (https://www.genecards.org/). Unique loss-of-function variants in X chromosomal tlr-7 were identified in four young men with severe COVID-19 [8], and rs179008 in tlr-7 gene have been related with increased risk to progress to advanced liver disease in hepatitis C virus (HCV) infection [9]. In the present case report, we identified a male child with the tlr-7 gene Gln11Leu single nucleotide polymorphism (rs 179008) with hepatitis and positive serological SARS-CoV-2 test. We also investigated other SNPs in the tlr-3, tirap, MCP-1, and oas-3 genes, and no mutation was detected.

Case presentation

A 5-years-old male child started with fever, odynophagia, diarrhea, abdominal pain, and vomiting on August 19, 2020. On the 23rd, still with fever, he developed acholic stool and jaundice. The child was hospitalized after medical evaluation and tests that detected hepatitis. The patient has asthma and extensively used beclomethasone spray at a low dose of 100 mcg/day. He had no other diseases, and this was his first hospital stay. On the child's vaccination card, there was one dose of hepatitis A and three doses of hepatitis B. After an interview with the child's caregivers, any possible accidental ingestion of drugs or hepatotoxic substances was also ruled out. The child remained hospitalized for supportive treatment and tests for 4 days, being discharged with improvement in fever, vomiting, and abdominal pain. However, the child was admitted again 4 days later because he had fever, tiredness, and edema in the lower limbs. He was discharged after 3 days. There was no bleeding or hemodynamic failure at any time. The patient received only supportive treatment. To investigate the possible cause of this hepatitis in this patient, serological tests for viral hepatitis (hepatitis A, B, C, E, HIV-1 and -2, EBV, and CMV), and tests to evaluate possible autoimmune hepatitis, Wilson's disease, and alpha1-antitrypsin deficiency, were performed (Table 1). All these tests were negative. The child shows a positive IgG for EBV and CMV. As the boy had one positive epidemiology for Covid-19 associated with fever, odynophagia and changes in inflammatory markers, coagulation profile, and D-dimer, a serological test was requested and was positive for IgM, IgG, and IgA for SARS-CoV-2, with the kits Biolisa-CoV-2 IgM, Biolisa-CoV-2 IgG, and Biolisa-CoV2 IgA (Bioclin, Quibasa, Brazil), respectively. The RT-qPCR for SARS-CoV-2 was performed from the nasopharynx and oropharynx 6 days after symptoms and was negative (Table 1). An echocardiogram was performed due to the possibility of multisystem inflammatory syndrome associated with covid-19, but the exam did not show changes in cardiac function or coronary dilation. After hospital discharge, the patient continues to be followed up on an outpatient clinic with a pediatric gastroenterology team, but without other clinical manifestations. The patient underwent cholangioresonance examination in January 2021, but the examination did not show any changes. At this time, the antinuclear antibody was also not reactive. Other diagnostic tests performed for differential diagnoses such as Wilson's disease, alpha-1-antitrypsin deficiency, autoimmune hepatitis, and primary sclerosing cholangitis were negative.
Table 1

Laboratory results, hepatitis tests, serological tests, and single nucleotide polymorphism genotype and phenotype

Tests (units)/dates08/24–2609/0211/18Reference range
Hemoglobin (g/dL)12.810.712.911.5–13.5
Leukocytes (cells/mm3)10,030845061705000–14,500
Platelets (cells/mm3)369,000589,000432,000150,000–400,000
C-Reactive protein (mg/L)23362< 12
Aspartate aminotransferase (IU/L)326483310–47
Alanine aminotransferase (IU/L)234491924–49
Bilirubin/direct bilirubin (mg/dL)4.4/4.00.9/0.60/0≤ 1.2/≤ 0.4
Gamma-glutamyl transferase (IU/L)83323922< 30
Alkaline phosphatase (IU/L)770329253142–335
Albumin (g/dL)3.93.94.32.9–4.7
Activated partial thromboplastin time (s)69627725–35
International normalized ratio (INR)1.281.381.30.87–1.2
D-dimer (mcg/mL)1.461.83≤ 0.5
α1-Antitrypsin (mg/L)29378–200
Ceruloplasmin (mg/dL)3620–60
Antinuclear antibody1:80NR
Anti-smooth muscleNRNR
Seric copper (mcg/dL)17790–190
Urinary copper (mcg/24 hs)11≤ 60
Anti-liver kidney microsome type 1NRNR
SARS-CoV-2 IgG/IgA/IgMP/P/PN
VDRLNN
RTqPCR influenza A, B; RSV and SARS-CoV2N/N/NN/N/N
Anti-human immunodeficiency virus 1,2NN
Anti-hepatitis A virus/C virusN/NN/N
Anti-hepatitis E IgMNN
Hepatitis B, HBsAg, anti-HBc-IgMN/N/NN/N/N
Anti-human herpes virus IgMNN
Anti-cytomegalovirus IgG/IgMP/NN
Anti-Epstein–Barr virus IgG/IgMP/NN
TLR-7 T/T (A/A)M
TLR-3 C/C (C/C)NH-
TIRAP C/C (C/C)NH
MCP-1 A/A (A/A)NH
OAS-3 C/C (C/C)NH

Bold means alterations in tests

MCP-1 monocyte chemoattractant protein 1, M mutated, non-functional, NH normal homozygote, OAS-3 2′-5′-oligoadenylate synthetase 3, SARS-CoV-2 severe acute respiratory syndrome coronavirus type 2, SNP single nucleotide polymorphism, RSV respiratory syncytial virus, TIRAP toll-interleukin 1 receptor domain-containing adapter protein, TLR-3 toll like receptor 3, TLR-7 toll like receptor 7, VDRL Venereal Disease Research Laboratory, P positive, N negative, NR non-reactive, – not done

Laboratory results, hepatitis tests, serological tests, and single nucleotide polymorphism genotype and phenotype Bold means alterations in tests MCP-1 monocyte chemoattractant protein 1, M mutated, non-functional, NH normal homozygote, OAS-3 2′-5′-oligoadenylate synthetase 3, SARS-CoV-2 severe acute respiratory syndrome coronavirus type 2, SNP single nucleotide polymorphism, RSV respiratory syncytial virus, TIRAP toll-interleukin 1 receptor domain-containing adapter protein, TLR-3 toll like receptor 3, TLR-7 toll like receptor 7, VDRL Venereal Disease Research Laboratory, P positive, N negative, NR non-reactive, – not done SNPs were selected based on previously reported associations with higher susceptibility of the host to other viral infections and with tlr genes, and proteins from the TLR activated cascade. Thereby, SNP rs179008 in the tlr-7 gene, rs3775291 in the tlr-3 gene, rs8177374 in the tirap gene, rs1024611 in the mcp-1 gene, and rs61942233 in the oas-3 gene were tested. The primers used were: 5′-AGAGAGGCAGCAAATGGGAA-3′ and 5′-TAGGAAACCATCTAGCCCCA-3′ for tlr-7, 5′-GCGAACTTTGACAAATGAAACA -3′ and 5′-CCCAACCAAGAGAAAGCATC-3′ for tlr-3, 5′-GGTGCAAGTACCAGATGCT-3′ and 5′-CAACGCATGACAGCTTCTTT-3′ for tirap, 5′-CTTCTCTCACGCCAGCAC-3′ and 5′-ACAGTAAACACAGGGAAGGT-3′ for mcp-1 and 5′-GCTGCTTCAGCCAGTTCA-3′ and 5′-GTCAGTGAGAAGCTCAGCA-3′ for oas-3. To detect SNPs, genomic DNA was extracted from peripheral blood, amplified by polymerase chain reaction (PCR), and sequenced. The genotype was confirmed by aligning the resulted sequence with the reference sequences from GenBank in the software Sequence Scanner 2.0 (Applied Biosystems), and novoSNP (Department of Molecular Genetics—VIB and University of Antwerp). No base change was detected on rs3775291 (tlr-3), rs8177374 (TIRAP), rs1024611 (mcp-1), and rs61942233 (oas-3), being a normal homozygote for these genes. A base change (A > T) was detected on rs179008 (tlr-7) SNP, being a mutated SNP, which causes an amino acid change (Q to L). The procedures were in accord with the ethical standards of the responsible committee on human experimentation from Instituto René Rachou, Fundação Oswaldo Cruz [CAAE 37207920.6.0000.5091] and with the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association and the patient's responsible written consent was obtained.

Discussion

At the beginning of the Covid-19 pandemic, few infections and severe cases in young adults and almost none in children were reported [1]. On February 8, 2021, Lachassinne et al. reported that the incidence of SARS-CoV-2 infection in children was still low [10]. We wondered why some of the children could be infected and developed a severe Covid-19. Liu and Hill [5] reported that primary immunodeficient patients could be more susceptible to severe infections, posing a high risk to Covid-19. Deficiency in antiviral innate immune signaling (TLRs, TIRAP) [5] or chemokines (MCP-1) essential to call the appropriated immune defense cells or in interferon-induced molecules (OAS-3) would be some targets to find the answer to this question. Initially, we addressed our efforts to verify if there were non-synonymous SNPs in DNA that codify these proteins, using the blood of children who needed to be admitted to the hospital. Although Covid-19 involves mainly the respiratory tract, there are some representative numbers of articles in the literature showing that several organs, including the liver and gastrointestinal tract, are also affected by SARS-CoV-2 [2-4]. Here we reported hepatitis, with gastrointestinal symptoms and fever in a 5-year-old male child, who was negative for hepatitis A, B, C, E, cytomegalovirus, Epstein Barr, syphilis, HIV, herpes, influenza, and respiratory syncytial virus. Additionally, the boy was positive for SARS-CoV-2 IgM, IgA, and IgG and presented one rs179008 in tlr-7. However, although immune tests were positive against SARS-CoV-2, a nasal swab collected 6 days after initial symptoms was RTq-PCR negative. Lack of detection of viral RNA 6 days after the first symptoms could be due to partial elimination of the virus confirmed by the presence of antibodies, or even the collection having been made traditionally only in the nasopharynx and oropharynx, since the child had no respiratory manifestations. Wang et al. 2021 [11] tested different clinical samples and detected SARS-CoV-2 in blood and feces. Kucirka et al. 2020 [12] also raised the question about the predictive value of the RTqPCR, which varies with time from exposure and symptom onset, predicting a reduction of 67% in the positivity on the fourth day. Hepatitis provoked by SARS-CoV-2 could be associated with the impaired innate immunity against the virus caused by the polymorphism in tlr-7 rs179008. The same SNP was reported by Fakhir et al. as being one of the causes of the impaired immune response during HCV infection [9]. Azar et al. (2020) reported patients infected with HIV-1, which presented the rs179008, produced lower quantities of TLR-7, resulting in lower production of IFN-1, with consequent higher viral load [13].

Conclusions

To our knowledge, this is the first report of a SARS-CoV-2 caused hepatitis in a male child that has the rs179008 tlr-7, which could impair an efficient initial immune response. The knowledge of the patient's immune deficiency could improve the treatment to correct this deficiency with specific medications.
  13 in total

1.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women.

Authors:  Pascal Azar; José Enrique Mejía; Claire Cenac; Arnoo Shaiykova; Ali Youness; Sophie Laffont; Asma Essat; Jacques Izopet; Caroline Passaes; Michaela Müller-Trutwin; Pierre Delobel; Laurence Meyer; Jean-Charles Guéry
Journal:  JCI Insight       Date:  2020-06-18

2.  Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression.

Authors:  Fatima-Zohra Fakhir; Mustapha Lkhider; Wafaa Badre; Rhimou Alaoui; Eliane F Meurs; Pascal Pineau; Sayeh Ezzikouri; Soumaya Benjelloun
Journal:  Liver Int       Date:  2017-08-24       Impact factor: 5.828

3.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens.

Authors:  Wenling Wang; Yanli Xu; Ruqin Gao; Roujian Lu; Kai Han; Guizhen Wu; Wenjie Tan
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

4.  Presence of Genetic Variants Among Young Men With Severe COVID-19.

Authors:  Caspar I van der Made; Annet Simons; Janneke Schuurs-Hoeijmakers; Guus van den Heuvel; Tuomo Mantere; Simone Kersten; Rosanne C van Deuren; Marloes Steehouwer; Simon V van Reijmersdal; Martin Jaeger; Tom Hofste; Galuh Astuti; Jordi Corominas Galbany; Vyne van der Schoot; Hans van der Hoeven; Wanda Hagmolen Of Ten Have; Eva Klijn; Catrien van den Meer; Jeroen Fiddelaers; Quirijn de Mast; Chantal P Bleeker-Rovers; Leo A B Joosten; Helger G Yntema; Christian Gilissen; Marcel Nelen; Jos W M van der Meer; Han G Brunner; Mihai G Netea; Frank L van de Veerdonk; Alexander Hoischen
Journal:  JAMA       Date:  2020-08-18       Impact factor: 56.272

Review 5.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

Review 6.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  W Joost Wiersinga; Andrew Rhodes; Allen C Cheng; Sharon J Peacock; Hallie C Prescott
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

7.  SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.

Authors:  Eric Lachassinne; Loïc de Pontual; Marion Caseris; Mathie Lorrot; Carole Guilluy; Aurélie Naud; Marie-Aliette Dommergues; Didier Pinquier; Evelyne Wannepain; Elisabeth Hausherr; Camille Jung; Vincent Gajdos; Robert Cohen; Jean-Ralph Zahar; Ségolène Brichler; Romain Basmaci; Pierre-Yves Boelle; Coralie Bloch-Queyrat; Camille Aupiais
Journal:  Lancet Child Adolesc Health       Date:  2021-02-08

8.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 9.  Liver injury during highly pathogenic human coronavirus infections.

Authors:  Ling Xu; Jia Liu; Mengji Lu; Dongliang Yang; Xin Zheng
Journal:  Liver Int       Date:  2020-03-30       Impact factor: 8.754

10.  Liver injury in COVID-19: management and challenges.

Authors:  Chao Zhang; Lei Shi; Fu-Sheng Wang
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-04
View more
  6 in total

Review 1.  Human genetic and immunological determinants of critical COVID-19 pneumonia.

Authors:  Qian Zhang; Paul Bastard; Aurélie Cobat; Jean-Laurent Casanova
Journal:  Nature       Date:  2022-01-28       Impact factor: 69.504

2.  Emerging cases of acute hepatitis of unknown origin in children amid the ongoing COVID-19 pandemic: Needs attention - Correspondence.

Authors:  Ranjan K Mohapatra; Venkataramana Kandi; Hardeep Singh Tuli; Sarika Verma; Sandip Chakraborty; Ali A Rabaan; Chiranjib Chakraborty; Kuldeep Dhama
Journal:  Int J Surg       Date:  2022-05-18       Impact factor: 13.400

3.  The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development-A Systematic Review.

Authors:  Marcin Goławski; Piotr Lewandowski; Iwona Jabłońska; Marcin Delijewski
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

4.  Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.

Authors:  Qian Zhang; Daniela Matuozzo; Jérémie Le Pen; Qiang Pan-Hammarström; Bertrand Boisson; Paul Bastard; Helen C Su; Stéphanie Boisson-Dupuis; Laurent Abel; Charles M Rice; Shen-Ying Zhang; Aurélie Cobat; Jean-Laurent Casanova; Danyel Lee; Leen Moens; Takaki Asano; Jonathan Bohlen; Zhiyong Liu; Marcela Moncada-Velez; Yasemin Kendir-Demirkol; Huie Jing; Lucy Bizien; Astrid Marchal; Hassan Abolhassani; Selket Delafontaine; Giorgia Bucciol; Gulsum Ical Bayhan; Sevgi Keles; Ayca Kiykim; Selda Hancerli; Filomeen Haerynck; Benoit Florkin; Nevin Hatipoglu; Tayfun Ozcelik; Guillaume Morelle; Mayana Zatz; Lisa F P Ng; David Chien Lye; Barnaby Edward Young; Yee-Sin Leo; Clifton L Dalgard; Richard P Lifton; Laurent Renia; Isabelle Meyts; Emmanuelle Jouanguy; Lennart Hammarström
Journal:  J Exp Med       Date:  2022-06-16       Impact factor: 17.579

Review 5.  Type I interferons and SARS-CoV-2: from cells to organisms.

Authors:  Paul Bastard; Qian Zhang; Shen-Ying Zhang; Emmanuelle Jouanguy; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2022-01-25       Impact factor: 7.486

Review 6.  An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.

Authors:  Mohammad Enamul Hoque Kayesh; Michinori Kohara; Kyoko Tsukiyama-Kohara
Journal:  Viruses       Date:  2021-11-18       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.